Skip to main content

Table 6 Incidence of treatment-related adverse events occurring during the whole studya

From: Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial

Disorder type ASAQ
(n = 184)
AL
(n = 182)
  Number (%)
  Mild Moderate Severe Mild Moderate Severe
Blood and lymphatic 7 (3.8) 2 (1.1) 1 (0.5) 8 (4.4) 2 (1.1) 0 (0.0)
Gastrointestinal 7 (3.8) 2 (1.1) 0 (0.0) 6 (3.3) 1 (0.5) 0 (0.0)
Nervous 7 (3.8) 1 (0.5) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0)
Skin, subcutaneous tissue 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0)
Respiratory, thoracic, mediastinal 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatobiliary 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
General 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0)
  1. aPercentage of patients experiencing an event/total safety population.